Www eu openscreen eu
This presentation is the property of its rightful owner.
Sponsored Links
1 / 29

eu-openscreen.eu PowerPoint PPT Presentation


  • 78 Views
  • Uploaded on
  • Presentation posted in: General

www.eu-openscreen.eu. Initiative for a European Research Infrastructure of Open Screening Platforms for Chemical Biology. Partners of preparatory phase project. EU-OPENSCREEN builds on national networks in 14 European countries. NOR-OPENSCREEN Swedish Chemical Biology Consortium

Download Presentation

eu-openscreen.eu

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Www eu openscreen eu

www.eu-openscreen.eu

Initiative for a

European Research Infrastructure of OpenScreening Platforms for Chemical Biology


Eu openscreen eu

Partners of preparatory phase project

EU-OPENSCREEN builds on national networks in 14 European countries.

  • NOR-OPENSCREEN

  • Swedish Chemical Biology Consortium

  • Drug Discovery and Chemical Biology network Finnland

  • Danish Chemical Biology Initiative

  • Dutch Chemical Library Program

  • ChemBioNet Germany

  • POL-OPENSCREEN

  • CZ-OPENSCREEN and Czech ChemGen

  • Austrian PLACEBO

  • Spanish ChemBioBank

  • French Chimiothèque Nationale, Réseau Nationale de Criblage, FR-OPENSCREEN

  • Romanian Chemical Biology Net

  • Flemish Network on Chemical Biology

  • Collezione Nazionale dei Composti Chimici e Centro Screening

Currentpartners

Associated members

CoordinationCentreat FMP Berlin


Eu openscreen eu

Chemical Biology

Investigation of biological systems using chemical tools

Infrastructures for the

European Research Area

23/09/2014

Page 3

3


Eu openscreen eu

Infrastructures for the

European Research Area

Biological &

Medical

Sciences

Understanding the

principles of life

Physics

Social Sciences

“Modern research in all scientific fields requires expensive instruments and resources, and is characterised by a continuous interplay between new scientific challenges and our technical responses to them.“ (ESFRI report)

Astronomy

Information

Technology


Eu openscreen eu

European Strategy Forum on Research Infrastructures (ESFRI)

Set up in 2002 by the Competitiveness Council.

Meeting of Senior Representatives for informal consultations on strategic issues related to research infrastructures (RI).

Independent from the European Commission.

2004: Mandate to develop a European Strategic Roadmap for Research Infrastructures - to describe the needs for the next 10 to 20 years - to identify vital new European research infrastructures.

Infrastructures for the

European Research Area


Esfri roadmap

ESFRI Roadmap

Published in October 2006, updated in 2008 and 2010.

Will be used to facilitate decision-making by member states and EC.

Will not prioritise or decide on funding and locations.

Four areas: Physical Sciences and Engineering (PSE), Biological and Medical Sciences (BMS), Social Sciences and Humanities (SSH), Environment (ENV).

Total: 48 ESFRI infrastructures.


Esfri bms fields of activity

ESFRI BMS – Fields of Activity

Biological Sciences

Biological Resources & Production Systems

Medical Sciences

Bioinformatics

Bio Banking & Molecular Resources

Clinical Research

Translational Medicine

Functional Genomics in the Mouse

Marine Biology

StructuralBiology

High Security Laboratories

Chemical Biology (EU-OPENSCREEN)

Imaging

Systems Biology

Ecosystems

Microbial Resources


Eu openscreen eu

ESFRI BMS – Fields of Activity

Towards supporting an

innovation chain without gaps

  • The EU-OPENSCREEN database will be linked to other biological databases through ELIXIR: BioMedBridges

  • Compounds with potential as drug candidates can be further developed through EATRIS and ECRIN

  • Cell-lines and animal models for bioprofiling of compounds are available through BBMRI and INFRAFRONTIER (BMS-RI) support

  • Natural products from MIRRI and EMBRC.

MIRRI

ANAEE

ISBE


Eu openscreen eu

EU-OPENSCREEN’s Mission

  • A pan-European infrastructure to...

  • accelerate the discovery of biologically active substances in all areas of the life sciences

  • facilitate transnational access to the most advanced technologies, chemical and biological resources, knowledge and expertise

  • advance the elucidation of the molecular mechanisms of complex biological processes

  • increase knowledge on the bio-activities of chemical substances, as well as the responses of biological systems to these substances

  • promote the availability of safe and efficacious chemical products for unmet needs in medicine, nutrition, agriculture, environment


The preparatory phase project

THE PREPARATORY PHASE PROJECT

WP1

Management and coordination

WP6

Governance

structure

WP7

Financial plan

WP8

IPR issues

Physical infrastructure

WP9

Chemical

Resources

WP12

Chem&

BioInformatics

WP5

Strategy

Advisory

Board

WP11

Technology

Resources

Steering Committee

WP10

Biology

Resources

MGT

Support

Team

WP2

Standardisation

WP3

Training and

education

WP4

Dissemination

and outreach


Advisory board

Advisory Board

Prof. Dr. Dr. Ernst Rietschel, former president of the Leibniz Association of Research centres (WGL), now acatech - National Academy of Science and Engineering(technology advisor for the German federal government)

Prof. Dr. Ferran Sanz, Director of GRIB (Research Group in Biomedical Informatics) at IMIM (Municipal Institute for Medical Research) in Barcelona. He is also a member of the Scientific Advisory Board for the Innovative Medicines Initiative (IMI).

Prof Dr. Serge Braun, scientific director of the Association Francaise contre les Myopathies (AFM)

Dr. Steve Rees, VP of Screening Sciences,AstraZeneca (AZ)


Expert groups

Expert Groups

Chemical Diversity Group (WP9) chaired by Dr.Michael Foley, Broad Institute, USA

Innovative Target & Assay Group (WP10) chaired by Sir Philip Cohen, UK

Industrial Advisory Group (WP5) chaired by Dr.Philip Gribbon, European ScreeningPort; members: J. Everett (f. Pfizer), J. Kihlberg (Univ. Uppsala, former AZ), T. Langer (Prestwick), H-U. Stilz (SA)

EU-OPENSCREEN Strategy Group (WP5) chaired by Dr.James Inglese, Chemical Genomics Centre, NIH, USA


Eu openscreen eu

OBJECTIVES

EU-OPENSCREEN´s objective is the development of novel research ‘tool’ compounds for all fields of the Life Sciences.

  • Tool compounds enable researchers to investigate molecular mechanisms of physiological and pathological processes, many of which can only be studied with these chemical ‘tools’

  • Chemical tools complement methods of molecular biology, such as mutagenesis or RNA interference

  • All generated tools and data are made publically available to the scientific community

Chemical keys for life’s locks

Chemical compounds, such as this small molecule, can bind to cellular structures (e.g. proteins) and modulate their functions.


Eu openscreen eu

A Chemical Biology Infrastructure

Serving research in all Life Sciences

No Life Without

Chemistry

Food

Ecology

VeterinaryMedicine

Medicine

Chemical Biology

Basic Research

Pest Control


Service portfolio

Service Portfolio

EU-OPENSCREEN will provide services to support the development of tool compounds at all stages


Eu openscreen eu

LAYOUT OF RI

EU-OPENSCREEN integrates Europe´s expert resources and facilities into its unique concept of a knowledge-creating Chemical Biology Centreand supports all stages of tool development projects in an RI ‘open’ for external researchers.

Biology

Assays & Targets

Chemistry

Compounds

meets

Partner Sites

User

User

Activity

profiles

Tool

compounds

Screening Technology

Chemistry Services

Compound Collection

Database

EU-OPENSCREEN-ERIC

Project Management

Training & Education

CompoundProfiling

Compound Management

Service contracts


Eu openscreen eu

UNIQUE ERIC ELEMENTS

The European Chemical Biology Library ECBL will

- be designed and built on the expert knowledge of European chemists

- cover unbiased chemical diversity with an expected size of 200k to 300k compounds

- be driven by the prospect of bioactivity, intellectual curiosity, uniqueness, and the goal of generating knowledge (not necessarily new chemical entities, NCEs)

- be composed to optimally serve the community and its needs; will contain selections from academic chemistry labs, commercial collections, known drugs, natural products, environmentals, etc.

- be quality controlled by approved standard method (LC-MS)

- be fully profiled with a set of basic properties (biophysical, cellular cytotoxicity, antimicrobial)

- be systematically profiled against hundreds of assays conducted by the network of screening centres.


Unique european assets

UNIQUE EUROPEAN ASSETS

  • The European Chemical Biology Database (ECBD) will be a web portal with powerful search and analysis capabilities:

    • contains validated output from screening centres in a public as well as pre-release environment.

    • supports curation, annotation and organization of data + metadata.

    • data deposition with flexible privacy model for rapid and safe dissemination and exploitation. Optional hold period of 18 months for data publication.

    • The broadest possible use of data through public accessibility and dissemination. Public data also freely available for complete download, redistribution.

    • High standards of security and traceability of IP (citable indexing of data points (EUOS, DOI or URL). Links to originator labs for primary raw unprocessed data.

    • Links to SAR (e.g. ChEMBL), Chemical Structure (e.g. PubChem), and Target (e.g. UniProt) resources. Links established with new NIH-funded BARD resource.


Project selection

Project Selection

Projects are evaluated by external reviewers and implemented according to milestones along a defined timeline.

Tool

compound

Validated chemical structure

Extensive basic Bio-profile

Bioactivity data from hundreds of assays


Eu openscreen eu

BUDGET (LIMITED CAPACITY)

Central costs

(6 years)

Shared funding

~ 27 m €

(e.g. GDP-share)

Project costs

(6 years)

Shared funding

~ 30 m €

(e.g. GDP-share,cost ceiling)

Shared funding of

Member countries

The required minimum budget for EU-OPENSCREEN is modest and shared between member countries.

Service site upgrades

National funding

Office

Upgrade 1

45 m€ already invested

Upgrade 2

ECBL

Upgrade 3

ECBD

Upgrade 4

Training

Upgrade 5


Eu openscreen eu

BUDGET (FULL CAPACITY)

Central costs

(6 years)

Shared funding

~ 27 M €

(e.g. GDP-share)

The required minimum budget for EU-OPENSCREEN is modest and shared between member countries.

Project costs

(6 years)

Diversefundingsources

~ 60 m€

Users

(research grants, in addition to EU-grants)

Service site upgrades

National funding

EU-funding to users (research grants)

Office

EU-funding to EU-OPENSCREEN

Upgrade 1

45 m€ already invested

Upgrade 2

ECBL

Upgrade 3

Shared funding of

Member countries

ECBD

Upgrade 4

Training

Upgrade 5


Added value

ADDED VALUE

  • EU-OPENSCREEN´s ‘open’ character: large pool of external biologists and chemists provide wide range of expertise, assays and diverse compounds.

Compounds

Compounds

Hit

FR

FR

UK

UK

Spanish target

DE

DE

Targets

Targets

ES

ES

French compound

IT

IT

x

x

Without EU-OPENSCREEN:

Limited chance of finding a hit against a target from local or national compound collections

With EU-OPENSCREEN:

European Scale Advantage: Exponential increase of the likelihood of finding a hit against a target from a national compound collection


Added value1

ADDED VALUE

  • EU-OPENSCREEN´s ‘open’ character: large pool of external biologists and chemists provide wide range of expertise, assays and diverse compounds.

Compounds

Compounds

UK

FR

Hit

FR

DE

Targets

UK

ES

Spanish target

DE

IT

Targets

x

ES

French compound

IT

Without EU-OPENSCREEN:

Limited chance of finding a hit against a target from local or national compound collections

With EU-OPENSCREEN:

European Scale Advantage: Exponential increase of the likelihood of finding a hit against a target from a national compound collection

x


Eu openscreen eu

IMPACT ON SCIENCE

In the Life Sciences, large-scale open-access research consortia have already proven fundamental to breakthroughs in their fields.

Weigelt (2009): “The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery.” EMBO Rep. 10: 941–945


Eu openscreen eu

IMPACT ON DRUG DISCOVERY

Public Sector Research Institutions (PSRI) contribute particularly to new NCEs and new indications.

Stevens, A.J. et al., 2011, N ENGL J MED 364:535-541.


Timeline

TIMELINE

Now in the 3rd year of its Preparatory Phase, EU-OPENSCREEN will initiate construction and operation in 2014-2015.

Roadmap

Preparation

Interim

Construction

Operation

  • ESFRI Roadmap: ESFRI considers EU-OPENSCREEN as vital to the excellence of research and innovation in Europe and included it on the “European Roadmap of Research Infrastructures”.

  • Preparatory Phase (3 years): Preparation of a business plan describing in detail the mode of construction and operation. MoU signed. EU funding: 3.7 M€.

  • Interim Phase (1-1.5 years): ERIC application and approval. Institutional funding.

  • Construction Phase (1 year): Construction of infrastructure (existing and new sites). National funding.

  • Operation Phase: Active infrastructure with access for researchers. Diverse funding sources.


Eu openscreen eu

CURRENT STATUS

AND NEXT STEPS

EU-OPENSCREEN was included on several national roadmaps and is now initiating negotiations with governments and funding organisations.

  • EU-OPENSCREEN in 3rd year of Preparatory Phase: Challenge before Construction and Operation Phases is the securing of (financial) commitment of member countries

  • Timelines of member countries vary: Transition Committee for the time between the end of the Preparatory Phase and the start of the Construction and Operation Phases will be formed

  • EU-OPENSCREEN included on several nationalRoadmaps

  • MoU document , financial plan, funding strategy,

  • draft ERIC statutes and draft Business Plan

  • already available

On national Roadmap  start negotiations

Decision expected in 2013

EU-OPENSCREEN – Executive Summary

Page 27

August 2013


Eu openscreen eu

Next Project & Stakeholder Meeting

Tuesday, 19 Nov – Project Meeting

09:00-13:00General Assembly meeting (project participants)

14:30-18:00 EU-OPENSCREEN outreach and synergies (invited guests) Interactions with representatives of other ESFRI infrastructures, JPI's and IMI´s European Lead Factory

19:30 EU-OPENSCREEN networking dinner

Wednesday, 20 Nov – Stakeholder Meeting

09:30-16:00EU-OPENSCREEN Science Day (open)

- 3 presentations from EU-OPENSCREEN

- 6 reports on flagship projects

13:00-16:00Transition Committee Meeting (closed)

Oslo

Norway


Eu openscreen eu

THE TEAM

Thank you for your attention

www.eu-openscreen.eu


  • Login